IRD · NASDAQ · Biotechnology

Opus Genetics (IRD)

Develops mutation-specific retinal gene therapies alongside partnered and investigational ophthalmology medicines.

$5.12
After-hours close−0.03 (−0.57%)
At close$5.15(−1.34%)